oxybutynin has been researched along with Nausea in 16 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Granisetron transdermal delivery system (GTDS) is the first 5-HT3 drug to be transdermally delivered and represents a convenient alternative to oral and intravenous antiemetics for the treatment of chemotherapy-induced nausea and vomiting." | 8.93 | Management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day highly or moderately emetogenic chemotherapy: role of transdermal granisetron. ( Coluzzi, F; Mattia, C, 2016) |
| "The findings indicate comparability of transdermal buprenorphine and transdermal fentanyl for pain measures with significantly fewer adverse events (nausea and treatment discontinuation due to adverse events) caused by transdermal buprenorphine." | 8.88 | Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. ( Aune, D; Hernandez, AV; Kleijnen, J; Misso, K; Riemsma, R; Truyers, C; Wolff, RF, 2012) |
| " The use of transdermal patches containing granisetron is thereby particularly indicated for the management of nausea and vomiting in these patients, ensuring a better quality of life and better compliance to the antineoplastic therapy." | 7.88 | [Management of nausea and vomiting in cancer patients. Use of transdermal patches containing granisetron in patients affected by head and neck squamous-cell carcinoma]. ( Gennari, A; Rondonotti, D, 2018) |
| " Of the volunteers who received the nicotine patch, four became anorexic and nauseated and two required anti-emetics." | 5.15 | A randomised double-blind crossover trial of the potential analgesic effect of a transdermal nicotine patch in non-smokers based on objective and subjective assessment. ( Fukada, T; Iwakiri, H; Ozaki, M, 2011) |
| "Granisetron transdermal delivery system (GTDS) is the first 5-HT3 drug to be transdermally delivered and represents a convenient alternative to oral and intravenous antiemetics for the treatment of chemotherapy-induced nausea and vomiting." | 4.93 | Management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day highly or moderately emetogenic chemotherapy: role of transdermal granisetron. ( Coluzzi, F; Mattia, C, 2016) |
| "The findings indicate comparability of transdermal buprenorphine and transdermal fentanyl for pain measures with significantly fewer adverse events (nausea and treatment discontinuation due to adverse events) caused by transdermal buprenorphine." | 4.88 | Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. ( Aune, D; Hernandez, AV; Kleijnen, J; Misso, K; Riemsma, R; Truyers, C; Wolff, RF, 2012) |
| " The use of transdermal patches containing granisetron is thereby particularly indicated for the management of nausea and vomiting in these patients, ensuring a better quality of life and better compliance to the antineoplastic therapy." | 3.88 | [Management of nausea and vomiting in cancer patients. Use of transdermal patches containing granisetron in patients affected by head and neck squamous-cell carcinoma]. ( Gennari, A; Rondonotti, D, 2018) |
| "The rivastigmine patch offers several advantages over the capsule form, including decreased peak to trough plasma fluctuations, reduced rates of nausea and vomiting, better treatment adherence, higher probability of reaching the target dose, ease of administration, and greater satisfaction among caregivers." | 3.83 | Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer's disease. ( Deardorff, WJ; Grossberg, GT; Nieto, RA, 2016) |
| " This study determined whether application of the AP to three different anatomical sites (lower abdomen, buttock and upper torso) influences the pharmacokinetic profile of EE and levonorgestrel (LNG)." | 2.78 | Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch. ( Archer, DF; Foegh, M; Rubin, A; Stanczyk, FZ, 2013) |
| " Migraine-associated gastroparesis can impair absorption and reduce bioavailability of oral migraine medications and thereby reduce and delay therapeutic efficacy." | 2.77 | Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system. ( Goldstein, J; Pierce, MW; Pugach, N; Silberstein, S; Singer, R; Smith, TR, 2012) |
| "Many migraineurs awake early in the morning with their attack progressing and already associated with nausea and vomiting." | 2.46 | Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine. ( Freitag, F; Pearlman, SH; Rapoport, AM, 2010) |
| "Safety and tolerability assessment included the monitoring and recording of adverse events and withdrawals at any time during the study." | 1.38 | Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions. ( Pregelj, P, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 14 (87.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Reiz, JL | 1 |
| Salem, P | 1 |
| Darke, AC | 1 |
| Ando, K | 1 |
| Suzuki, A | 1 |
| Yoshida, H | 1 |
| Hindmarsh, J | 1 |
| Hindmarsh, S | 1 |
| Lee, M | 1 |
| Telford, R | 1 |
| Rondonotti, D | 1 |
| Gennari, A | 1 |
| Martin, CM | 1 |
| Pieris, N | 1 |
| Baldwin, AD | 1 |
| DeSilva, P | 1 |
| Wong, M | 1 |
| Nieto, RA | 1 |
| Deardorff, WJ | 1 |
| Grossberg, GT | 1 |
| Coluzzi, F | 1 |
| Mattia, C | 1 |
| Chung, SJ | 1 |
| Asgharnejad, M | 1 |
| Bauer, L | 1 |
| Ramirez, F | 1 |
| Jeon, B | 1 |
| Chowdhury, NA | 1 |
| Sewatsky, ML | 1 |
| Kim, H | 1 |
| Rapoport, AM | 1 |
| Freitag, F | 1 |
| Pearlman, SH | 1 |
| Fukada, T | 1 |
| Iwakiri, H | 1 |
| Ozaki, M | 1 |
| Smith, TR | 1 |
| Goldstein, J | 1 |
| Singer, R | 1 |
| Pugach, N | 1 |
| Silberstein, S | 1 |
| Pierce, MW | 1 |
| Wolff, RF | 1 |
| Aune, D | 1 |
| Truyers, C | 1 |
| Hernandez, AV | 1 |
| Misso, K | 1 |
| Riemsma, R | 1 |
| Kleijnen, J | 1 |
| Pregelj, P | 1 |
| Stanczyk, FZ | 1 |
| Archer, DF | 1 |
| Rubin, A | 1 |
| Foegh, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Granisetron Transdermal Delivery System for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Agents: a Single-center, Single-arm, Phase II Trial[NCT04472143] | Phase 2 | 60 participants (Anticipated) | Interventional | 2020-07-18 | Recruiting | ||
| Double Blind, Placebo-controlled, Parallel, Multicenter, Randomized Interventional Phase IV Study to Evaluate the Efficacy of Rotigotine on Depressive Symptoms in Idiopathic Parkinson's Disease Patients[NCT01523301] | Phase 4 | 380 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months[NCT00792103] | Phase 3 | 198 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The combined score of UPDRS part II and UPDRS part III is the sum of the individual scores and threfore ranges from 0 (normal) to 160 (severe). (NCT01523301)
Timeframe: From Baseline (Week 0) to end of Maintenance Period (up to Week 15)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Efficacy Evaluable Set (Rotigotine Treated Subjects) | -4.20 |
| Efficacy Evaluable Set (Placebo Treated Subjects) | -1.81 |
The AS is an abbreviated version of the Apathy Scale (AS). The AS consists of 14 items phrased as questions that are to be answered on a four-point Likert scale. It was developed specifically for patients with Parkinson Disease (PD). For questions 1-8, the scoring system is the following: not at all = 3 points; slightly = 2 points; some =1 point, a lot = 0 point. For questions 9-14: the scoring system is the following: not at all = 0 points; slightly = 1 point; some = 2 points; a lot = 3 points. Adding all scores provides the final score with a range from 0 to 42. (NCT01523301)
Timeframe: From Baseline (Week 0) to end of Maintenance Period (up to Week 15)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Efficacy Evaluable Set (Rotigotine Treated Subjects) | -1.93 |
| Efficacy Evaluable Set (Placebo Treated Subjects) | -0.67 |
The Beck Depression Inventory II (BDI-II) is a self-report instrument to measure Depression symptoms and severity. There are 21 items in the BDI-II. Scores of 0-13 are considered minimal depression; 14-19 indicates mild depression; 20-28 indicates moderate depression; and 29-63 indicates severe depression. (NCT01523301)
Timeframe: From Baseline (Week 0) to end of Maintenance Period (up to Week 15)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Efficacy Evaluable Set (Rotigotine Treated Subjects) | -5.87 |
| Efficacy Evaluable Set (Placebo Treated Subjects) | -4.68 |
The SHAPS is a self-report instrument developed for the assessment of hedonic capacity. The sum of the 14 items scores ranges from 0 to 14. A higher score represents more anhedonic symptoms. (NCT01523301)
Timeframe: From Baseline (Week 0) to end of Maintenance Period (up to Week 15)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Efficacy Evaluable Set (Rotigotine Treated Subjects) | -0.82 |
| Efficacy Evaluable Set (Placebo Treated Subjects) | -0.60 |
The HAM-D consists of 17 items. Nine of the items are scored on a 5-point scale, ranging from 0 to 4. The remaining 8 items are scored on a 3-point scale, from 0 to 2. Therefore, the total score ranges between 0 to 52, with a cutoff score of 15/16 diagnosing major depressive disorder. (NCT01523301)
Timeframe: From Baseline (Week 0) to end of Maintenance Period (up to Week 15)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Efficacy Evaluable Set (Rotigotine Treated Subjects) | -4.79 |
| Efficacy Evaluable Set (Placebo Treated Subjects) | -3.68 |
The UPDRS Part II is a tool to measure Activities in Daily Living - it includes speech, salivation, swallowing, handwriting, cutting food and handling utensils, dressing, hygiene, turning in bed and adjusting clothes, falling (unrelated to freezing), freezing when walking, walking, tremor, and sensory complaints related to Parkinsonism. Each of the 13 questions is measured on a scale from 0 (normal) to 4 (severe). The total score of UPDRS part II ranges from 0 (normal) to 52 (severe). (NCT01523301)
Timeframe: From Baseline (Week 0) to end of Maintenance Period (up to Week 15)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Efficacy Evaluable Set (Rotigotine Treated Subjects) | -1.13 |
| Efficacy Evaluable Set (Placebo Treated Subjects) | -0.10 |
Improvement of motor symptoms is measured by the change from Baseline in UPDRS Part III motor score. The UPDRS Part III is an accepted and validated scale for the assessment of motor function in Parkinson's disease. Each of the elements in the UPDRS Part III is measured on a scale of 0 to 4, where 0 is normal and 4 represents severe abnormalities. The total score of UPDRS part III ranges from 0 (normal) to 108 (severe abnormalities). (NCT01523301)
Timeframe: From Baseline (Week 0) to end of Maintenance Period (up to Week 15)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Efficacy Evaluable Set (Rotigotine Treated Subjects) | -3.07 |
| Efficacy Evaluable Set (Placebo Treated Subjects) | -1.65 |
Nausea free at two hours after patch activation. (NCT00792103)
Timeframe: 2 hours
| Intervention | participants (Number) |
|---|---|
| NP101 | 143 |
Headache pain relief (no pain or mild headache pain) at two hours post activation of NP101. (NCT00792103)
Timeframe: 2 hours
| Intervention | participants (Number) |
|---|---|
| NP101 | 105 |
Phonophobia free at two hours after patch activation. (NCT00792103)
Timeframe: 2 hours
| Intervention | participants (Number) |
|---|---|
| NP101 | 109 |
Photophobia free at two hours after patch activation. (NCT00792103)
Timeframe: 2 hours
| Intervention | participant (Number) |
|---|---|
| NP101 | 97 |
For each patch application, subjects performed a self-examination of skin irritation using a 5-point scale (0=no redness; 1=minimal skin redness; 2=moderate skin redness with sharp borders; 3=intense skin redness with or without swelling; 4=intense skin redness with blisters or broken skin). (NCT00792103)
Timeframe: 24 hours post patch activation
| Intervention | scores on a scale (Mean) |
|---|---|
| NP101 | 1.0 |
3 reviews available for oxybutynin and Nausea
| Article | Year |
|---|---|
Management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day highly or moderately emetogenic chemotherapy: role of transdermal granisetron.
Topics: Antiemetics; Antineoplastic Agents; Granisetron; Humans; Nausea; Transdermal Patch; Vomiting | 2016 |
Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine.
Topics: Clinical Trials as Topic; Drug Administration Routes; Female; Gastroparesis; Humans; Iontophoresis; | 2010 |
Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain.
Topics: Administration, Oral; Analgesics, Opioid; Buprenorphine; Chronic Pain; Constipation; Fentanyl; Human | 2012 |
5 trials available for oxybutynin and Nausea
| Article | Year |
|---|---|
Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin.
Topics: Adolescent; Adult; Area Under Curve; Cross-Over Studies; Delayed-Action Preparations; Dizziness; Hea | 2007 |
Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson's disease.
Topics: Activities of Daily Living; Aged; Depression; Dopamine Agonists; Double-Blind Method; Female; Humans | 2016 |
A randomised double-blind crossover trial of the potential analgesic effect of a transdermal nicotine patch in non-smokers based on objective and subjective assessment.
Topics: Administration, Cutaneous; Adult; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Nau | 2011 |
Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Chemistry, Pharmaceutical; Female; Follow-Up Stu | 2012 |
Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch.
Topics: Abdomen; Adult; Buttocks; Cohort Studies; Contraceptive Agents, Female; Cross-Over Studies; Drug Com | 2013 |
8 other studies available for oxybutynin and Nausea
| Article | Year |
|---|---|
Possible Effect of Blonanserin Transdermal Patch on Antiemetic Control in Patients With Terminal Cancer with Refractory Nausea.
Topics: Antiemetics; Antipsychotic Agents; Ascites; Humans; Nausea; Neoplasms; Transdermal Patch; Vomiting | 2023 |
The combination of levomepromazine (methotrimeprazine) and rotigotine enables the safe and effective management of refractory nausea and vomiting in a patient with idiopathic Parkinson's disease.
Topics: Administration, Cutaneous; Aged; Antiparkinson Agents; Antipsychotic Agents; Dopamine Agonists; Fema | 2019 |
[Management of nausea and vomiting in cancer patients. Use of transdermal patches containing granisetron in patients affected by head and neck squamous-cell carcinoma].
Topics: Antiemetics; Antineoplastic Agents; Granisetron; Head and Neck Neoplasms; Humans; Male; Middle Aged; | 2018 |
Lessons learned from hospice care.
Topics: Aged; Aged, 80 and over; Amitriptyline; Analgesics, Opioid; Drug Monitoring; Fentanyl; Health Servic | 2013 |
Unequal pupils following removal of hyoscine patch.
Topics: Adolescent; Anisocoria; Antineoplastic Agents; Humans; Male; Mydriatics; Nausea; Precursor Cell Lymp | 2014 |
Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Humans; Nausea; Rivastigmine; Transdermal P | 2016 |
Transdermal Scopolamine Withdrawal Syndrome Case Report in the Pediatric Cerebral Palsy Population.
Topics: Adolescent; Antiemetics; Botulinum Toxins, Type A; Cerebral Palsy; Delayed Diagnosis; Humans; Inject | 2017 |
Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibit | 2012 |